Cover Image
市場調查報告書

上海醫藥股份有限公司的產品平台分析

Shanghai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 321353
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
上海醫藥股份有限公司的產品平台分析 Shanghai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 27 Pages
簡介

上海醫藥股份有限公司是在中國及海外進行醫療保健產品的製造及流通、銷售的企業。經手心血管系統治療藥、全身的抗感染藥、消化器官藥及免疫代謝藥、神經精神系藥、抗癌藥物等,擁有藥局網路及40間以上的製造工廠。

本報告提供上海醫藥股份有限公司的治療藥開發平台的現狀及各開發階段比較分析、各藥物標的、作用機制、給藥途徑、分子類型的治療藥的評估、最新的企業新聞和發表、後期階段及中止的計劃相關資訊等。

目錄

上海醫藥股份有限公司 的基本資料

  • 上海醫藥股份有限公司 概要
  • 主要資訊
  • 企業資料

上海醫藥股份有限公司 :R&D概要

  • 主要的治療範圍

上海醫藥股份有限公司 :開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

上海醫藥股份有限公司 :開發中產品概況

  • 在臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段有的開發中產品
    • 前臨床階段的產品/聯合治療模式

上海醫藥股份有限公司 :藥物簡介

  • thalidomide
  • Hydroxytriptolide
  • Deuteporfin
  • LLTD-8
  • Small Molecules to Inhibit 11 Beta Hydroxysteroid Dehydrogenase 1 for Metabolic Diseases

上海醫藥股份有限公司 :開發平台分析

  • 各標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

上海醫藥股份有限公司 :開發休止的計劃

上海醫藥股份有限公司 :企業理念

上海醫藥股份有限公司 :總公司和子公司的所在地

  • 總公司
  • 分公司及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07538CDB

Summary

Global Markets Direct's, 'Shanghai Pharmaceutical Co., Ltd. - Product Pipeline Review - 2015', provides an overview of the Shanghai Pharmaceutical Co., Ltd.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Shanghai Pharmaceutical Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Shanghai Pharmaceutical Co., Ltd. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Shanghai Pharmaceutical Co., Ltd.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Shanghai Pharmaceutical Co., Ltd.'s pipeline products

Reasons to buy

  • Evaluate Shanghai Pharmaceutical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Shanghai Pharmaceutical Co., Ltd. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Shanghai Pharmaceutical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Shanghai Pharmaceutical Co., Ltd. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Shanghai Pharmaceutical Co., Ltd.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Shanghai Pharmaceutical Co., Ltd. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Shanghai Pharmaceutical Co., Ltd. Snapshot
    • Shanghai Pharmaceutical Co., Ltd. Overview
    • Key Information
    • Key Facts
  • Shanghai Pharmaceutical Co., Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline Products Glance
    • Shanghai Pharmaceutical Co., Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Shanghai Pharmaceutical Co., Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Shanghai Pharmaceutical Co., Ltd. - Drug Profiles
    • Deuteporfin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • thalidomide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Hydroxytriptolide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LLTD-8
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit 11 Beta Hydroxysteroid Dehydrogenase 1 for Metabolic Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline Analysis
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline Products by Target
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline Products by Route of Administration
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline Products by Molecule Type
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action
  • Shanghai Pharmaceutical Co., Ltd. - Dormant Projects
  • Shanghai Pharmaceutical Co., Ltd. - Company Statement
  • Shanghai Pharmaceutical Co., Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Shanghai Pharmaceutical Co., Ltd., Key Information
  • Shanghai Pharmaceutical Co., Ltd., Key Facts
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline by Indication, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Phase II, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Phase I, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Preclinical, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline by Target, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline by Route of Administration, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline by Molecule Type, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline Products by Mechanism of Action, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Dormant Developmental Projects,2015
  • Shanghai Pharmaceutical Co., Ltd., Other Locations
  • Shanghai Pharmaceutical Co., Ltd., Subsidiaries

List of Figures

  • Shanghai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Indication, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline by Stage of Development, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Monotherapy Products in Pipeline, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Target, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Route of Administration, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline by Top 10 Molecule Type, 2015
  • Shanghai Pharmaceutical Co., Ltd. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top